NLRP3 and cystic fibrosis: Therefore, since anakinra will block both the effects of IL-1β and IL-1α and in addition has impact on several key inflammatory mechanisms such as NLRP3 inflammasome activation and autophagy, anakinra might be beneficial in CF by targeting multiple pathogenic mechanisms.